Sugi Predict

Sugi Predict / Compounds / SCHEMBL7704763

SCHEMBL7704763

SCHEMBL7704763

O=C(O)c1ccnc(C(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 8/20 0.55
▸ KDM5C P41229 7/20 0.55
▸ KDM4A O75164 6/20 0.55
▸ KDM2A Q9Y2K7 5/20 0.55
▸ KDM3A Q9Y4C1 5/20 0.55
▸ KDM5B Q9UGL1 5/20 0.55
▸ KDM4E B2RXH2 4/20 0.55
▸ KDM6B O15054 4/20 0.55
▸ KDM5A P29375 2/20 0.55
▸ KDM4D Q6B0I6 2/20 0.55
▸ TET3 O43151 1/20 0.55
▸ BBOX1 O75936 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ ASPH Q12797 1/20 0.55
▸ TET2 Q6N021 1/20 0.55
▸ ALKBH5 Q6P6C2 1/20 0.55
▸ KDM7A Q6ZMT4 1/20 0.55
▸ KDM8 Q8N371 1/20 0.55
▸ TET1 Q8NFU7 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453118 1.00 KDM4C (0.55) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL25709497 0.85 KDM4C (0.52) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL28976353 0.85 KDM4C (0.52) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL28205115 0.85 KDM4C (0.41) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL12136051 0.83 SMARCA2 (0.49) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL7704773 0.83 SMARCA2 (0.49) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL16094229 0.83 SMARCA2 (0.45) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL23583774 0.82 KDM4C (0.57) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL25342268 0.82 KDM4C (0.49) KDM4CKDM5CKDM4AKDM2AKDM3A
SCHEMBL1759894 0.81 KDM4C (0.55) KDM4CKDM5CKDM4AKDM2AKDM3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. 2025-01-16 — — US disclosed
EP-4399210-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES Black Diamond Therapeutics, Inc. (US) 2024-07-17 — — EP disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
CN-118159537-A 6-Aza-quinoline derivatives and related uses 黑钻治疗公司 2024-06-07 — — CN disclosed
CN-118103364-A Pyrazinyl-triazole compounds as pesticides 拜耳公司 2024-05-28 — — CN disclosed
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2024-05-16 — — US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 — — US disclosed
WO-2015181747-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS NOVARTIS AG (CH) 2015-12-03 — — WO disclosed
WO-2015180612-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-03 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20110281894-A1 HEMIFUMARATE SALT ASTRAZENECA AB (SE) 2011-11-17 — — US disclosed
WO-2011142716-A1 NOVEL HEMIFUMARATE SALT OF ISOINDOLE COMPOUND ACTING AS BACE INHIBITOR ASTRAZENECA AB (SE) 2011-11-17 — — WO disclosed
US-20110281894-A1 HEMIFUMARATE SALT ASTRAZENECA AB (SE) 2011-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281894-A1 HEMIFUMARATE SALT PSEN1, PSEN2, SNCA KDM4C 4009/4885KDM5C 3619/4885KDM4A 3631/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 KDM4C 1502/4885KDM5C 1577/4885KDM4A 1280/4885
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 KDM4C 1502/4885KDM5C 1577/4885KDM4A 1280/4885
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS KDM4C 1872/4885KDM5C 2082/4885KDM4A 1688/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 KDM4C 1347/4885KDM5C 1221/4885KDM4A 917/4885
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES TOP2A, TOP2B, UGT2B7 KDM4C 270/4885KDM5C 316/4885KDM4A 1053/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 KDM4C 2710/4885KDM5C 2185/4885KDM4A 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.